Summary
For Year 2026-27, Piramal Pharma reports the following shareholding: Total Promoters at 34.86%, Mutual Fund at 14.12%, Insurance at 1.24%, Foreign Institutional Investors at 30.17%, Domestic Institutional Investors at 0.26%, and Retail at 19.36%. This breakdown provides a quick snapshot of ownership distribution for Piramal Pharma in 2026-27.
Piramal Pharma FAQs
As of 04-2026, the promoter shareholding in Piramal Pharma stands at 34.86% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Piramal Pharma is 30.17% and 0.26% respectively.
The retail shareholding of the Piramal Pharma is 19.36%.
Changes in shareholding patterns of Piramal Pharma can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Piramal Pharma are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
